SARS-CoV-2 Remdesivir

Remdesivir is a brand-new nucleotide analog prodrug with the development code GS-5734 that has broad-spectrum antiviral activity. In a number of animal models, it has been identified as a promising antiviral treatment against an extensive range of RNA viruses infection, including SRAS and MERS. The SARS-CoV-2 remdesivir integrates into developing viral RNA chains as an adenosine analogue and causes premature termination. Additionally, the research has demonstrated that remdesivir effectively prevents virus infection in Huh-7 cells from human liver cancer, which are susceptible to SARS-CoV-2.